The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis ; volume:24 ; number:1 ; day:12 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
BMC gastroenterology ; 24, Heft 1 (12.11.2024), 1-9, 12.2024
- Creator
-
Hu, Xinyue
Tang, Xiaowei
Li, Limin
Luo, Lian
He, Xinsen
Yan, Qin
Zhong, Xiaolin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-024-03480-9
- URN
-
urn:nbn:de:101:1-2501292107316.170178181811
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hu, Xinyue
- Tang, Xiaowei
- Li, Limin
- Luo, Lian
- He, Xinsen
- Yan, Qin
- Zhong, Xiaolin
- SpringerLink (Online service)
Other Objects (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
PF-06438179/GP1111: An Infliximab Biosimilar
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching